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Abstract
Background: Gambling is a legal form of entertainment in 48 states and is enjoyed by many. In
Approximately 1% of the population, casual gaming can turn into pathological gambling (PG) resulting in
devastating consequences. There are currently no guidelines or regulations for clinical providers regarding the
most effective treatments of PG. Previous research has shown opioid antagonist to be effective in treating
similar addictions such as alcoholism and heroin. How effective are opioid antagonist in the treatment of
pathological gambling?
Methods: An exhaustive search of Medline-OVID, CINAHL, PSYCHINFO, Evidence Based Medicine
Reviews Multifile, and Web of science using keywords: gambling, drug therapy, and narcotic antagonist.
Limitations included studies in the English language and on humans. Articles pertaining to the area of interest
were evaluated using GRADE.
Results: Three studies met inclusion criteria which are discussed in this systematic review. A randomized
double-blind, placebo-controlled trial with 112 participants showed statistically significant reduction in
gambling behaviors and urges with 18 weeks of treatment with naltrexone. Another randomized double-blind,
placebo-controlled trial with 233 participants failed to show significant decrease in gambling behaviors and
urges with 18 weeks of treatment with nalmefene compared. Finally, a case study showed complete cessation
of gambling behavior and urges with intramuscular monthly injections of naltrexone.
Conclusion: Opioid antagonist drug naltrexone may be an effective option for treating pathological gambling
whereas a similar drug nalmefene seems to be ineffective. Due to the low quality of evidence, effective
injectable naltrexone effective dosing is undetermined.
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Abstract   
Background: Gambling is a legal form of entertainment in 48 states and is enjoyed by many.  
In Approximately 1% of the population, casual gaming can turn into pathological gambling 
(PG) resulting in devastating consequences.  There are currently no guidelines or regulations 
for clinical providers regarding the most effective treatments of PG.  Previous research has 
shown opioid antagonist to be effective in treating similar addictions such as alcoholism and 
heroin.  How effective are opioid antagonist in the treatment of pathological gambling? 
 
Methods:  An exhaustive search of Medline-OVID, CINAHL, PSYCHINFO, Evidence 
Based Medicine Reviews Multifile, and Web of science using keywords: gambling, drug 
therapy, and narcotic antagonist.  Limitations included studies in the English language and on 
humans.  Articles pertaining to the area of interest were evaluated using GRADE. 
 
Results:  Three studies met inclusion criteria which are discussed in this systematic review.  
A randomized double-blind, placebo-controlled trial with 112 participants showed 
statistically significant reduction in gambling behaviors and urges with 18 weeks of treatment 
with naltrexone.  Another randomized double-blind, placebo-controlled trial with 233 
participants failed to show significant decrease in gambling behaviors and urges with 18 
weeks of treatment with nalmefene compared.  Finally, a case study showed complete 
cessation of gambling behavior and urges with intramuscular monthly injections of 
naltrexone. 
 
Conclusion:  Opioid antagonist drug naltrexone may be an effective option for treating 
pathological gambling whereas a similar drug nalmefene seems to be ineffective.  Due to the 
low quality of evidence, effective injectable naltrexone effective dosing is undetermined. 
 
Keywords:  gambling, drug therapy, narcotic antagonist. 
  
 - 4 -  
Acknowledgements 
 
 To Jake Hedges, Thank you for your love and support through this journey. 
 
   
 
 - 5 -  
Table of Contents 
 
Biography ............................................................................................................................ 2 
Abstract ............................................................................................................................... 3 
Acknowledgements ............................................................................................................. 4 
Table of Contents ................................................................................................................ 5 
List of Tables ...................................................................................................................... 6 
List of Abbreviations .......................................................................................................... 6 
BACKGROUND ................................................................................................................ 7 
METHODS ......................................................................................................................... 7 
RESULTS ........................................................................................................................... 7 
DISCUSSION ................................................................................................................... 12 
CONCLUSION ................................................................................................................. 14 
References ......................................................................................................................... 15 
Table I. Characteristics of Reviewed Studies ................................................................... 16 
Table II. Summary of Findings ......................................................................................... 17 
 
  
 - 6 -  
List of Tables  
 
Table I:       Characteristics of Reviewed Studies 
Table II:     Summary of Finding 
 
List of Abbreviations 
 
CBT………………………………………………………………Cognitive Behavior Therapy 
CGI-S…………………………………Clinically Global Impressions-Severity of Illness scale 
G-SAS............................................................................Gambling Symptom Assessment Scale 
HAM-A……………………………...……..…………The Hamilton Rating scale for Anxiety 
HAM-D……………………………………...…………Hamilton Rating Scale for Depression 
PG………………………………………………………………………Pathological gambling 
PG-YBOCS..Pathological Gambling Adaptation of Yale-Brown Obsessive Compulsive Scale 
SDS…………………………………………..… ………………...…Sheehan Disability Scale 
SOGS……………………………………………………………South Oaks Gambling Screen 
 
 
 
 
 - 7 -  
Efficacy of Opioid Antagonist in the Treatment 
of Pathological Gambling. 
 
BACKGROUND 
 
Currently in the United States, 48 states have some form of legalized gambling with 
the exception of Utah and Hawaii.  Furthermore, the increase of internet gaming and casinos 
could potentially lead to an increase in PG.  This easy access to gaming has the potential to 
create problematic and pathological gambling which affects approximately 1% of the US 
population.
1
 Pathological gambling (PG) is a disorder that affects an individual financially, 
socially, and psychologically.  The DSM-5 defines PG as a “persistent and recurrent 
maladaptive gambling behavior that disrupts personal, family, or vocational pursuits.”2   
There are currently no protocols or guidelines in place for first line therapy in the 
treatment of PG.  Opioid antagonist drugs have been shown to be effective treatment in 
similar compulsive disorders such as alcoholism and heroin addiction.
3,4 
 Naltrexone and 
nalmefene (not available in US) are two opioid antagonists that may be useful in treating PG.  
The need for clear definition of effective treatments for PG needs to be established for 
healthcare providers to successfully provide adequate care.   
METHODS 
 
An exhaustive literature search was conducted using Medline-OVID, CINAHL, 
PSYCHINFO, Evidence Based Medicine Reviews Multifile, and Web of science using 
keywords: gambling, drug therapy, and narcotic antagonist. The search was further limited to 
the English language, research conducted in the United States, and human studies.  Articles 
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pertaining to the area of interest were evaluated using Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE).
5
 
RESULTS 
 
The original search yielded 13 articles.  After eliminating non-relevant articles, three were 
included for review.  These articles included two randomized control trials,
6,7
 and one case 
study.
8 
 See Table I and Table II. 
Naltrexone vs Placebo 
 
This randomized, double blind placebo controlled study
6
 evaluated the safety and 
efficacy of three oral doses of naltrexone for the treatment of PG.  Participants were obtained 
through newspaper advertisements. Recruits consisted of both men and women ages 18 to 75 
years with a primary diagnosis of PG according to DSM-IV-TR criteria.  Inclusion criteria 
included; a score of 2 or higher on the Gambling Symptom Assessment Scale (G-SAS), a 
score of 5 or higher on the South Oaks Gambling Screen (SOGS), and had a gambling 
encounter within 14 days of initiation of participation.
6
   
Exclusion criteria included gambling less than once a week, not meeting DSM-IV-TR 
criteria for PG, unstable medical condition including abnormal laboratory tests, EKG, or 
physical exam upon enrollment.  Women who were pregnant, lactating or not providing 
adequate birth control methods were excluded.  A need for medication with contraindications 
with naltrexone, history of bipolar disorder, dementia, schizophrenia, substance abuse or 
dependence, positive urine drug screen, cognitive behavioral therapy within the past 3 
months, previous treatment of naltrexone, baseline score of 26 or higher on the 24-item 
Hamilton Rating Scale for Depression (HAM-D), suicidality, treatment with investigational 
medication or neuroleptics within past 3 months, treatment with fluoxetine within 4 weeks or 
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psychotropic drugs 2 weeks before study initiation would also exclude participation in the 
study.
6 
The length of the study was 18 weeks. Eighty three eligible participants began a 1-week 
placebo.  At the start of the 2nd week, if G-SAS scores had reduced by 50%, participants 
were deemed placebo responders and eliminated.  Computer generated randomization 
assigned the remaining 77 subjects to four groups: 50mg/day, 100mg/day, 150mg/day, or 
placebo.  Due to known adverse side effects of naltrexone all subjects were started at 
25mg/day or placebo for 2 days and titrated up to the assigned group dosage by the first day 
of week 3.  Compliance was evaluated by measuring urine florescence to detect riboflavin 
which was inserted into each capsule.
6 
PG symptoms were assessed with the Pathological Gambling Adaptation of the Yale-
Brown Obsessive Compulsive Scale (PG-YBOCS) and severity was assessed using the 
SOGS
 
, G-SAS, and the Clinical Global Impressions-Severity of Illness scale (CGI-S). 
Anxiety, depression, and psychosocial functioning were also assessed using the HAM-A,
 
HAM-D,
 
 and Sheehan Disability Scale (SDS).
 
 Participants were assessed weekly for two 
months and the remaining 10 weeks were assessed every two weeks.
6 
Twenty eight participants dropped out of the study.  A lack of differences between the 
three naltrexone groups in regards to baseline characteristics, treatment completion, 
compliance, adverse drug reactions, and study outcomes led to the data of all groups being 
combined and compared to placebo. After 6 weeks of treatment 39.7% of those assigned to 
naltrexone had abstained completely from gambling for at least 1 month. After 6 weeks of 
those assigned to the placebo only 10.5% had abstained from gambling for at least 1 month.  
The PG-YBOCS, G-SAS, CGI-S, SDS all demonstrated improvement in scores in the 
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naltrexone groups.  The Hamilton Rating scale for Anxiety (HAM-A) and HAM-D scores did 
not show an improvement in any study group.  No changes to liver function or clinical 
findings occurred with the treatment of naltrexone.  The study concluded that naltrexone was 
superior to placebo in the treatment of PG.  Results also revealed that treatment outcomes 
were similar at 50mg, 100mg, and 150mg doses. Higher doses of naltrexone were not 
correlated with better outcomes.
6 
Limitations identified by the researches of this study included the length of the study 
being 18 weeks.  PG has been identified as a chronic problem and longer treatment studies 
are needed.  Also the study was limited to participants desiring a pharmacological 
intervention for PG excluding all psychotherapy treatment modalities.  The authors identified 
that further research in the combination of naltrexone and cognitive behavior therapy are 
needed.
6 
Nalmefene vs Placebo 
This randomized, double blind, placebo controlled study
7
 evaluated the safety and 
efficacy of two oral doses of nalmefene for the treatment of PG over 16 weeks. All research 
was funded by Somaxon pharmaceuticals.  Participants were recruited via newspaper 
advertisement and consisted of both men and women ages ranging from 18-70.  The research 
took place at 25 outpatient centers throughout the United States. Inclusion criteria included a 
score of 21 or higher on the PG-YBOCS
 
, a score >5 on one criteria of the Sheehan Disability 
Scale (SDS)
 
, and had a gambling even within one month of enrollment.  Exclusion criteria 
consisted of a concurrent Axis I disorder, receiving treatment for gambling, and unstable 
medical illness.
7 
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 All participants began a one week placebo which was single-blinded.  Participants 
who scored 15 or greater on the PG-YBOCS after the one-week placebo trial were 
randomized using a computer generated assignment to three groups: nalmefene 20mg/day, 
40mg/day, or placebo.  Due to known adverse drug reactions to opioid antagonist all 
randomized participants during week 2 began a 5mg/day dose of nalmefene or placebo 
equivalent.  Doses were increased during week 3 according to assigned group.  The PG-
YBOCS total score was used to determine the primary outcome and G-SAS and SDS scores 
were used to measure secondary outcomes.  Two hundred twenty-three randomized 
participants were prognostically balanced and used in analysis of the results.
7
 
 Seventy-seven participants were assigned to 20mg/day dose, 82 were in the 40mg/day 
dose, and 74 took the placebo. Placebo responders eliminated accounted for 46.8% in the 
20mg/day, 56.1% in the 40mg/day, and 59.5% in the placebo group were eliminated after the 
first week.  Analysis of the comparison of treatment response at either dose failed to show 
nalmefene was more effective than placebo (F=1.741, d.f.=2, P=0.178).  However, post hoc 
analysis revealed that participants who had a fully titrated dose for a minimum of one week 
had improved PG-YBOCS scores, specifically a decrease in urges for gambling.
7
   
The researchers identified that the poor results may have been due to the large 
number of treatment centers involved in the trial. Further investigation into the large portion 
of participant drop outs, 27% prior to the full titration dose in the treatment groups.  Dropout 
rates may be due to adverse drug reactions of nalmefene or extraneous factors that should be 
accounted for in future research.  A further limitation identified was the length of research.  
PG effective treatment may require longer than 18 weeks for improvement in urges and 
behavior.
 7 
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Injectable Naltrexone 
This case study
8
 involved a 58 year old male with a history of alcohol dependence 
and depression in remission who became a PG after the initiation of taking pramipexole for 
restless leg syndrome.  Although his restless leg symptoms ceased he began having urges to 
gamble and suffered losses of over $100 000.  The patient was titrated up to 200mg/day of 
oral naltrexone as prescribed by his clinician.  Treatment of his restless leg was switched 
from pramipexole to clonazepam.  After two weeks of treatment the patient reported no 
decrease in symptoms and gambling losses continued up to $2 000 a month even post 
pramipexole cessation.  The patient admitted to poor compliance with the oral naltrexone. An 
inpatient residential, 5-week intervention program was attempted but unsuccessful.  A trial of 
380mg/month injected intramuscularly naltrexone was initiated and within a month the 
patient reported no intent to gamble.  Clonazepam was not effective in treating his restless 
leg symptoms and was started on pramipexole again.  With the combination of pramipexole 
and injectable naltrexone the patient was able to abstain from all gambling for 12 months.
8 
DISCUSSION 
 
Opioid antagonist drugs have an important role in the treatment of PG.  Oral and 
injectable naltrexone was shown to be beneficial in decreasing gambling urges and total 
cessation of gambling behavior.  Nalmefene was originally thought to be a better opioid 
antagonist pharmaceutical choice over naltrexone due it its longer half-life, stronger affinity 
for muscarinic opioid receptors, and no known associated liver toxicity.  However, the 
randomized clinical trials,
6,7
 showed naltrexone to be superior to nalmefene.  Nalmefene was 
shown to be equal to and in some cases less beneficial in treating overall PG recovery than 
the placebo. 
7 
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Although the naltrexone randomized clinical trial
6
 and the case study
8
 showed promising 
results for PG treatment there were limitations with these findings.  The recruitment for the 
naltrexone RCT
6 
was done through newspaper advertisement. Although inclusion and 
exclusion criteria were followed to participate in the trial, this type of recruitment involves 
participants already with a desire to quite gambling.  This may have led to elevated results in 
both the treatment group and the placebo.   
Both RCTs
6,7  
had a considerable amount of subjects terminate participation prematurely.  
The naltrexone study
6 
had a 36% dropout and the nalfemene study
7
 had a 27%.  It is unclear 
in both studies for the reason of attrition rates.   Further investigation of whether adverse 
drug or lack of interest in continuing treatment lead to the discontinuation of participation. 
The case study
8
 is severely limited due to a sample size of 1.  The results cannot be 
generalized to the PG community until a larger study is performed using injectable 
naltrexone for decreasing gambling urges and behaviors. 
Limitations to the Nalmefene RCT
7 
were similar to the naltrexone RCT
6
 in that they used 
the same form of recruitment.  This may have led to the results showing the placebo being 
more effective than nalmefene due to the participants desire to seek help and cease gambling 
behavior from the start of the trial.  Future studies should involve participants should include 
persons with a PG diagnosis with the desire to stop gambling and those with no desire to stop 
to measure to true effectiveness of treatment.  
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CONCLUSION 
 
Due to the lack of recommended first line treatments or protocols by American medical 
associations for treatments of PG, opioid antagonist naltrexone is a viable option for 
clinicians.  A 50mg/day oral dose of naltrexone may be appropriate for treatment of adults 
with PG.  If non-compliance leads to treatment failure, injectable naltrexone is a 
consideration if no other options are available.  Future research is necessary in order to fully 
understand opioid antagonist use in the treatment of PG.
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Table I. Characteristics of Reviewed Studies 
a as evidenced by subgroup analysis participants were not on the study long enough 
bHigh attrition rate 
cFunded by Somaxon pharmaceutical but study failed to show significant results 
dSmall sample size 
Quality Assessment 
  
Study Detail Downgrade Criteria 
 
Participants Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
 
Quality 
A Double-Blind, Placebo-controlled Study of the Opiate Antagonist Naltrexone in the Treatment of Pathological Gambling Urges.
6
 
112 RCT  
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No 
 
High 
Nalmefene in the Treatment of Pathological Gambling: multicenter, double-blind, placebo-controlled study.
7
 
 233  RCT Serious  limitationsa 
No serious 
indirectness Serious imprecision
b No serious 
inconsistencies No
c 
 
Low 
 Monthly Injectable Naltrexone for Pathological Gambling.
8
 
 1  Case Study  Serious limitationsd  - - - - 
Very Low 
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Table II. Summary of Findings 
 
 
 
 
 
 
Summary of Findings Importance 
 
Number of Patients 
Effect 
  
 
Study Opioid Antagonist Placebo  Baseline End Point      Effect size 
p-value/ 
CI 
PG-YBOCS total score  
Naltrexone vs placebo 
36 13 
Placebo18.6±4.90 
Naltrexone 16.9± 6.60 
Placebo12.9± 9.31  
Naltrexone 9.7±8.12 
3.05 .009 
 
Critical 
Nalmefene vs placebo 
20mg n=59 
40mg n = 57 
n= 71 
Placebo 21.98 
Nalmefene 20mg 21.17 
Nalmefene 40mg 20.75 
Placebo 11.29-12.26 
Nalmefene 20mg 11.34-12.30 
Nalmefene 40mg 6.06-7.21  
20mg = 0.49 
40mg = -1.96 
95% 
 
Critical 
IM Naltrexone  
1 0 - - - - 
 
PG-YBOCS urge scale  
Naltrexone vs placebo 
36 13 
Placebo10.2±2.66 
Naltrexone 9.5±3.54 
Placebo7.1± 4.73 
Naltrexone 5.5±4.16 
 1.66 .005  
 
Critical 
Nalmefene vs placebo 
20mg n=59 
40mg n = 57 
n= 71 
Placebo 11.33 
Nalmefene 20mg 10.83 
Nalmefene 40mg 11.09 
Placebo 6.01-6.48 
Nalmefene 20mg 5.74-6.22 
Nalmefene 40mg 4.04-4.61 
20mg = 0.49 
40mg = -1.96 
95% 
 
Critical 
IM Naltrexone  
1 0 - - - - 
 
